Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej

Blood (2019) 134 (Supplement_1): 2791.

https://doi.org/10.1182/blood-2019-122974

Published: 2019

Journal Articles

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Chia Sharpe, Joanne Davis, PhD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Dale I Godfrey, PhD, Adam Uldrich, PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2018-99-117618

Published: 2018

Journal Articles

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Eric Wong, MBBS, Emily Dawson, Joanne Davis, PhD, Rachel Koldej, PhD, Mandy Ludford-Menting, Matthew Lansdown, Heather Lambie, Jeffrey Szer, MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, David Ritchie, MBChB, PhD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 4633.

https://doi.org/10.1182/blood-2018-99-112310

Published: 2018

Journal Articles

Pharmacological Control of Recipient NK Cell Function By Venetoclax Promotes Engraftment and Limits GVHD Following Reduced Intensity Conditioning without Impacting the Graft Versus AML Effect

Joanne Davis, PhD, Yuhao Jiao, Nicholas Huntington, PhD, David Ritchie, MD PhD

Blood (2017) 130 (Supplement 1): 3177.

https://doi.org/10.1182/blood.V130.Suppl_1.3177.3177

Published: 2017

Journal Articles

In Vitro Efficacy of Agonistic Antibody to TRAIL-R1 (Mapatumumab) and Low Dose Bortezomib in Multiple Myeloma

Paul Neeson, PhD, Karen Chen, Tsin Tai, MSc, Amanda Shin, Joanne Davis, PhD, H. Miles Prince, MD, David S. Ritchie, MD, PhD

Blood (2008) 112 (11): 5169.

https://doi.org/10.1182/blood.V112.11.5169.5169

Published: 2008

NARROW

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Pharmacological Control of Recipient NK Cell Function By Venetoclax Promotes Engraftment and Limits GVHD Following Reduced Intensity Conditioning without Impacting the Graft Versus AML Effect

In Vitro Efficacy of Agonistic Antibody to TRAIL-R1 (Mapatumumab) and Low Dose Bortezomib in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Pharmacological Control of Recipient NK Cell Function By Venetoclax Promotes Engraftment and Limits GVHD Following Reduced Intensity Conditioning without Impacting the Graft Versus AML Effect

In Vitro Efficacy of Agonistic Antibody to TRAIL-R1 (Mapatumumab) and Low Dose Bortezomib in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only